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Abstract: Iron-platinum alloy nanoparticles (FePt NPs) are extremely promising candidates for the next
generation of contrast agents for magnetic resonance (MR) diagnostic imaging and MR-guided interventions,
including hyperthermic ablation of solid cancers. FePt has high Curie temperature, saturation magnetic
moment, magneto-crystalline anisotropy, and chemical stability. We describe the synthesis and characteriza-
tion of a family of biocompatible FePt NPs suitable for biomedical applications, showing and discussing
that FePt NPs can exhibit low cytotoxicity. The importance of engineering the interface of strongly magnetic
NPs using a coating allowing free aqueous permeation is demonstrated to be an essential parameter in
the design of new generations of diagnostic and therapeutic MRI contrast agents. We report effective cell
internalization of FePt NPs and demonstrate that they can be used for cellular imaging and in vivo MRI
applications. This opens the way for several future applications of FePt NPs, including regenerative medicine
and stem cell therapy in addition to enhanced MR diagnostic imaging.
1. Introduction
Nanoparticles (NPs) have attracted considerable interest as
diagnostic and therapeutic tools for biomedicine,
1-3 with
magnetic NPs offering unique opportunities for magnetic
separation, targeted drug delivery, and hyperthermic ablation
of cancer and as contrast agents in magnetic resonance imaging
(MRI).
4-11 MRI is a powerful, noninvasive medical imaging
technique where the signal originates predominately from water
and lipids. Medical diagnosis requires enhanced contrast
between normal and pathological tissues, resulting in the
development of exogenous MRI contrast agents.
12 Common T2-
agents include superparamagnetic nanoparticles (Fe3O4, γ-Fe2O3,
MnFe2O4, FeCo), the clinical MRI applications of which range
from imaging lymph-node to liver and spleen, as well as bone
marrow and gastrointestinal tract.
4,13,14 Despite its widespread
usage, superparamagnetic iron oxide (SPIO) has several disad-
vantages, including rapid clearance by phagocytic cells and
hence limited trans-endothelia passage and tissue penetration.
4,15
There is therefore a need for the design of biocompatible MRI
contrast agents with prolonged intravascular retention, improved
tissue delineation, high chemical stability, and improved
selectivity when targeting a tissue of interest.
Small NPs avoid fast clearance by the reticulo-endothelial
system and therefore should enable long blood circulation half-
life, thereby improving their ability to reach speciﬁc targets.
4,16
Silica is often considered as the most attractive coating for
engineered NPs, forming an inert and biocompatible outer shell.
Not only does it create a protective shell against chemical
degradation, but it also allows surface functionalization with
functional alkoxysilanes.
7 An outer coating with functional
organic molecules has many advantages, including steric and/
or electrostatic repulsion between the NPs, which can increase
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Positively charged NPs demonstrate increased cell internalization
efﬁciency and biomedical molecules binding capability for
multimodal imaging applications and drug delivery.
4,18,19
Characterized by high Curie temperature and magneto-
crystalline anisotropy, iron-platinum metallic alloy NPs have
emerged as promising candidates for a new generation of
magnetic nanomaterials.
20 Over the past decade, several chemi-
cal pathways have been developed to synthesize FePt NPs with
controlled stoichiometry, size, and shape.
5 Such synthetic routes
include co-reduction of Fe and Pt precursors through both low-
temperature emulsion protocols and the high-temperature polyol
pathway,
21-25 along with the thermal decomposition route.
26-31
The latter approach often relies on Pt(acac)2, Fe(CO)5,o r
Collman’s regeant precursors mixed with alkyl amines and acids
solubilized in high-boiling-point solvents heated at temperatures
of ∼300 °C and above to control the growth, composition, and
morphology of the NPs.
Studies have demonstrated the biomedical potential of FePt
NPs,
6 such as in magnetic separation
32,33 and hyperthermic
ablation
34,35 and as T2 MRI contrast agents.
36-38 However,
toxicity remains a major concern, preventing their use as a
bioplatform for diagnosis and therapy.
37,39,40
In this article, we describe the fabrication of FePt NPs
speciﬁcally designed to enhance their magnetic properties for
biomedical applications. We demonstrate that, in contrast with
previous reports, FePt NPs can be made nontoxic, and we
provide the ﬁrst data on their cellular uptake mechanisms. We
report a 6-fold increase in the FePt-based T2 contrast properties
compared to those of clinical iron oxide NPs. The relationship
between the MRI contrast properties and the NPs’ architecture
is explored and rationalized as the basis for the design of NPs
as enhanced MRI contrast agents. Finally, we report the ﬁrst
observations of cellular and in ViVo MR imaging with FePt NPs.
Our results opens the way for several applications of FePt NPs,
such as regenerative medicine and stem cell therapy, in addition
to enhanced MR diagnostic imaging, thus providing a platform
to develop novel diagnostic and therapeutic agents.
2. Results
Figure 1 displays the schematic structure of a clinical iron
oxide NP coated with dextran (Feridex, Figure 1A1) and two
FePt NPs: the face-centered-cubic (fcc) FePt NP surface
functionalized with cysteamine (fcc-FePt-A, Figure 1B1) and
the fcc FePt NP coated with silica and surface-functionalized
with (3-aminopropyl)triethoxysilane (fcc-FePt-silica-A, Figure
1C1). The preparation of the family of FePt NPs is described
in the Supporting Information.
27,30,17,41
In agreement with published literature,
42 transmission electron
microscopy (TEM) revealed that the commercial iron oxide NPs
samples (Figure 1A2) are composed of aggregated crystals
approximately 5 nm in diameter, embedded in an organic
coating. These aggregates form large particles of a size
distribution ranging from 20 to >50 nm. In contrast, the fcc-
FePt-A NPs are well dispersed, with diameters of ∼5 nm (Figure
1B2). The fcc-FePt-silica-A NPs are coated with a homogeneous
silica shell of ∼17 nm in thickness, leading to a total diameter
of ∼40 nm (Figure 1C2).
The powder X-ray diffraction (XRD) pattern of the Feridex
iron oxide conﬁrms the presence of magnetite (Fe3O4), the broad
peaks at 38°,4 5 °, and 55° corresponding to the (220), (311),
and (400) peaks, respectively (Figure 1A3). Figure 1B3,C3
shows peaks around 51° and 60°, characteristic of fcc-FePt (111)
and (200) peaks, respectively. The (111) peak position suggests
that the NPs’ composition includes between 40 and 45% of Fe
(Table 1). For the silica-coated NPs, the SiO2 XRD characteristic
peak is observed at ∼28° (Figure 1C3). The crystal size is ∼3.6
nm for both fcc-FePt-A and fcc-FePt-silica-A NPs (Table 1).
Zero-ﬁeld-cooling and ﬁeld-cooling (ZFC-FC) of Feridex
samples highlight a 45 K blocking temperature (Tb, Figure 1A4).
At 2 K, i.e., lower than Tb, Feridex hysteresis loop measurements
display ferrimagnetic behavior with a small coercivity value of
300 Oe and a saturation moment (Ms) of 101 emu/g of Fe. At
300 K, Feridex is superparamagnetic with no coercivity, as
illustrated in Figure 1A5. The Ms value is 82 emu/g of Fe, in
agreement with the literature.
16,42 In comparison, the fcc-FePt-A
NPs have a higher Tb of ∼90 K (Figure 1B4). More importantly,
when compared to Feridex, the Ms of fcc-FePt-A NPs is ∼2
times larger at 2 K and 35% stronger at 300 K (Figure 1B5,
Table 1). After silica coating, the blocking temperature is
reduced to 50 K, and the ZFC slope below Tb is steeper (Figure
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a
Ms (emu/g Fe)
sample DXRD (nm) FexPt1-x (%) Tb (K) at 2 K at 300 K Hc at 2 K (kOe) r1
b (s-1 mM-1) r2
b (s-1 mM-1)
fcc-FePt-A 3.6 ( 0.1 42.7 ( 0.7 90 201 112 0.7 2.5 ( 1.0 887 ( 32
fcc-FePt-silica-A 3.6 ( 0.1 43.8 ( 1.4 50 191 83 1.3 0.3 ( 0.1 210 ( 3
Feridex I.V.
c (Endorem) 5.3 ( 0.1 - 45 101 82 0.3 0.9 ( 0.1 148 ( 2
a DXRD is the crystalline grain size of the NPs; in FexPt1-x, x is the composition based on the FePt lattice constant (SI-Figure 1);
43 Tb is the blocking
temperature; Ms is the saturation moment; Hc is the magnetic coercivity of the NPs; and r1 and r2 are the 1H relaxivity values for 1% agarose gel
containing Feridex, fcc-FePt-A, and fcc-FePt-silica-A NPs.
b A range of other commercial MRI contrast agent relaxivity values are presented in the
Supporting Information (SI-Table 2).
c Trademark of AMAG Pharmaceuticals, Lexington, MA.
Figure 1. Schematic representation (1), TEM images (2), XRD patterns (3), ZFC-FC (4), and hysteresis (5) curves of Feridex (A1-A5), fcc-FePt-A NPs
(B1-B5), and fcc-FePt-silica-A NPs (C1-C5).
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ARTICLES Chen et al.1C4). At 2 K and 5 T, the magnetization of fcc-FePt-silica-A
NPs is ∼5% lower than that of fcc-FePt-A and 2 times larger
than that of Feridex. At 300 K and 5 T, the magnetization of
fcc-FePt-silica-A NPs is ∼36% lower than that of fcc-FePt-A
NPs and similar to that of Feridex (Figure 1C5, Table 1).
Cytotoxicity of the NPs was evaluated in an A375M cell line
using fcc-FePt-A NPs and MTS assay with various concentra-
tions and incubation times.
43 Both dose-response and time
course studies were performed (Figure 2A). As expected,
44,45
and in contrast with bare iron oxide,
46,47 Feridex’s dextran
organic coating does not lead to any detectable cytotoxicity.
At 120 µg/mL, fcc-FePt-A NPs exhibited cytotoxicity that
increases with incubation time. At a concentration of 60 µg/
mL, fcc-FePt-A NPs incubated with cells for 7 days showed a
∼15% loss of cell viability. Signiﬁcantly, there is no loss of
cell viability at concentrations of 30 µg/mL and below, even
after prolonged incubation periods of up to 7 days. Similar
results were obtained with fcc-FePt-A NPs and both MCF7 and
U2OS tumor cell lines (SI-Figure 5A,B).
43
To conﬁrm these results, the chemical stability of fcc-FePt-A
NPs in an acidic environment was investigated by incubation
of fcc-FePt-A in pH 4.8 buffer solutions. The concentration of
FePt NPs incubated in buffer solution is ∼120 µg/mL, to match
the highest NPs concentration used in the cytotoxicity study
(Figure 2A). In a pH 4.8 phosphate buffered saline (PBS),
cysteamine-coated FePt NPs show excellent chemical stability,
with only ∼0.6% Fe, i.e. <0.1 µg/mL, of iron released after 7
days of incubation (Figure 2B1). As suggested by the recent
literature,
48,49 an in Vitro lysosomal model, i.e. RPMI-1640 cell
media containing 20 mM sodium citrate (pH 4.8), was also used
to match the metabolic conditions. In these more extreme
conditions (Figure 2B2), more Fe was releaseds0.3 µg/mL after
6 h and up to ∼3.3 µg/mL after 7 dayssbut importantly it
remained at a level comparable to the release observed with
Feridex.
The high chemical stability of fcc-FePt-A was investigated
further. Prussian blue staining experiments were carried out and
showed that FePt NPs have greater stability compared to Feridex
(Figure 2C1-C3).
43 Indeed, photomicrographs obtained after
overnight incubation show no stain for both blank control sample
(Figure 2C1) and cells labeled with fcc-FePt-A NPs (Figure
(43) See Supporting Information for details.
(44) Wang, L. J.; Wang, Z. G.; Frank, T. G.; Brown, S. I.; Chudek, S. A.;
Cuschieri, A. Nanomedicine-UK 2009, 4, 305–315.
(45) Dobrovolskaia, M. A.; McNeil, S. E. Nat. Nanotechnol. 2007, 2, 469–
478.
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28, 323–329.
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Frank, J. A. NMR Biomed. 2005, 18, 383–389.
Figure 2. Viability of A375M cells incubated with fcc-FePt-A NPs (A). Fe released from fcc-FePt-A NPs (orange [) in pH 4.8 PBS (B1). Fe released from
fcc-FePt-A NPs (orange [) and from Feridex (4)
49 in solutions at pH ∼4.8 of RPMI-1640 cell media containing 20 mM sodium citrate. The incubation
concentrations for FePt and Feridex
49 were 120 and 25 µg/mL, respectively (B2). Photomicrographs (magniﬁcation ×40) of Prussian blue-stained A375M
cells cultured on coverslips in cell media (C1), media containing 30 µg/mL of fcc-FePt-A NPs (C2), and media containing 30 µg/mL of Feridex (C3) after
overnight incubation. TEM images of A375M cells after 16 h incubation in media containing 30 µg/mL of fcc-FePt-A NPs (D1-D3).
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staining (Figure 2C3) characteristic of the release of Fe in the
cells. These results conﬁrm that the cysteamine coating provides
fcc-FePt-A NPs with high chemical stability.
The cysteamine coating is positively charged, resulting in
higher cellular uptake by human non-phagocytic A375M tumor
cells (Figure 2D1-D3) compared to Feridex. FePt NPs appear
to be internalized by an endocytotic pathway. Indeed, TEM
studies suggest a macropinocytosis cellular uptake mechanism
by the large protrusions of the plasma membrane around NP
clusters (Figure 2D2).
50,51 The intracellular localization route
is endosome, early lysosome, and late lysosome, which are basic
cell biology phenomena. Both endosomes and lysosomes are
conﬁned subcellular organelles, and, as both expected and
commonly observed in other NPs systems, the FePt NPs appear
typically “entrapped” inside these subcellular vesicles (Figure
2D3).
The effectiveness of fcc-FePt-A and fcc-FePt-silica-A as MRI
contrast agents was investigated by measuring the dependence
of the longitudinal relaxation rate (T1
-1) and transverse relax-
ation rate (T2
-1) of 1% agarose gels.
43 Relaxivity (ri) quantiﬁes
the enhancement of either the longitudinal or the transverse
relaxation rates of the protons in water. As expected at high
magnetic ﬁeld, the FePt NPs and Feridex have a weak inﬂuence
on the water 1H longitudinal relaxation rate (Table 1 and
SI-Figure 7A).
16,43 In contrast, FePt NPs have a signiﬁcant effect
upon the aqueous transverse relaxation rate (Figure 3A1). The
relaxivity r2 of the fcc-FePt-silica-A NPs is 40% larger than
that of Feridex, which is attributed to the stronger magnetic
moment of the fcc-FePt-silica-A NPs (SI-Figure 7B) at the MRI
magnetic ﬁeld (7 T).
43 Importantly, the relaxivity r2 of the fcc-
FePt-A NPs is more than 6 times larger than that of Feridex.
(50) Conner, S. D.; Schmid, S. L. Nature 2003, 422, 37–44.
(51) Kirkham, M.; Parton, R. G. Biochim. Biophys. Acta 2005, 1745, 273–
286.
Figure 3. T2
-1 (s-1) vs [Fe] (mM) of the water in 1% w/v agarose gel containing (blue b) fcc-FePt-A, (green 2) fcc-FePt-silica-A, and (orange [) Feridex
(A1). 1H longitudinal relaxation time T2-weighted MRI images of 1% agarose gel/water solution containing fcc-FePt-A NPs with [Fe] ) 0.00 mM (a), 0.02
mM (CFePt ) 6 µg/mL) (b), and 0.04 mM (CFePt ) 12 µg/mL) (c) (A2). T2-weighted cellular imaging by MRI (3D spin echo, TE ) 30 ms, TR ) 1s )o f
A375M cells loaded with fcc-FePt-A NPs with a cell density of 10 × 103 cells/mL (a), 100 × 103 cells/mL (b), and 1000 × 103 cells/mL (c) (B). Embryo
injected in oVo with cell culture media (1 µL) containing no NPs (C) and 20 µg/mL fcc-FePt-A (D). 3D surface reconstruction of embryo eyes (blue) and
blood vessels (red) showing the position in yellow of the transverse and coronal images (C1,D1); dorsal view of transverse image of the embryo’s head
aligned through the eyes (C2,D2); and anterior view of coronal image of the embryo’s head aligned through the eyes (C3,D3). 2D slices from 128 × 128
× 128 3D Rare-8 MRI data set of day 4 quail embryo egg (TR/TE ) 250/25 ms), ﬁeld of view of 30 mm and pixel dimensions of 0.234 mm/pixel. Labels:
y, yolk; a, albumen; b, brain; in-e, injected eye; un-e, un-injected eye; h, heart. Scale bar indicates 1 mm. All the MRI measurements were completed at 7.1
T.
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concentrations of fcc-FePt-A NPs in agarose gels. The signal
intensity reduces and the image appears darker as the NPs
concentration increases. The FePt NPs produce an observable
change in image contrast at concentrations as low as 6 µg/mL,
which is well within the safety range indicated by the cytotox-
icity data (Figure 2A). Similarly, signal intensity loss was
observed in cells labeled with fcc-FePt-A NPs as the cell density
increases from 10 × 103 to 1000 × 103 cells/mL (Figure 3B).
The in ViVo potential of FePt NPs as MRI contrast agents
was demonstrated by injecting NPs in cell culture media into
the eyes of day 4 quail embryos in oVo. Figure 3C,D displays
3D MRI image data sets after injection. The transverse and
coronal images through the embryo’s head are presented. The
uninjected eye (un-e) acts as an internal control. There is no
difference in the contrast between the uninjected and the
uppermost eye (in-e) which had been injected with a 1 µLo f
culture medium only (Figure 3C2,C3). However, when the
injection medium contained 20 µg/mL of fcc-FePt-A NPs, a
very distinct hypointensity appears in the injected eye (Figure
3D2-D3). This was consistently observed when varying the
NPs concentration.
This thus demonstrates the capability of nontoxic FePt NPs
as potent MRI probes for cellular imaging, even at very low
NP concentrations. Labeling the cells and these magnetic NPs
will allow, for instance, cell migration to be studied, with their
biodistribution and behavior monitored in ViVo, especially as
we have demonstrated that the effect of contrast agents can be
observed at non-cytotoxic concentrations lower than 30 µg/mL.
3. Discussion
The major hurdle preventing the wider use of FePt NPs in
biomedicine is their potential toxicity. In the literature, there
are many inconsistencies in FePt cytotoxicity, leaving the subject
rather confused. A summary of the cytotoxicity data of FePt
NPs is presented in Table 2. While it was reported that 24 h
incubation of FePt-cysteine NPs had no signiﬁcant toxicity at
concentrations below 5 µg/mL, these compounds resulted in
50% cell damage at 15.5 µg/mL;
39 FePt-Fe3O4 NPs showed no
signiﬁcant cell viability damage up to 3 days of incubation at
10 µg/mL.
37 In contrast, FePt-Fe2O3 and FePt-CoS2 were
reported to induce signiﬁcant cell viability damage of over 50%
even at concentrations of NPs as low as 1.5 and ∼8.3 µg/mL,
respectively.
37,39 A recent toxicity study with phospholipids-
coated fcc-FePt NPs showed 50% cell viability damage above
1.25 µg/mL Fe concentration (∼7.8 µg/mL Fe40Pt60 NPs).
52 In
this latter study, the high toxicity was attributed to fast Fe release
from phospholipids-coated fcc-FePt NPs. It was reported that
∼6% Fe was already released after6ho fincubation, and the
percentage of Fe released increased to ∼20% after 24 h of
incubation in pH 4.8 PBS.
52 While iron is essential for almost
all living organisms, it is toxic. It can act as a catalyst in the
Fenton reaction, which generates a wide range of free radical
species, including hydroxyl radicals. These are among the most
reactive free radical species known and have the ability to react
with a wide range of cellular constituents, including pyrimidine
bases of DNA, and also to trigger lipid peroxidation in cellular
membranes, leading to cell death.
53
In this study, the fcc-FePt-silica-A NPs have good biocom-
patibility and, as expected, the silica coating forms an inert shell
(SI-Figure 5C).
43 In contrast to previously published results,
our study demonstrates that cysteamine-coated fcc-FePt NPs
also have very high chemical stability in pH 4.8 PBS. Fe release
after 24 h of incubation is only ∼0.3%, with only a slight
increased to 0.6% after 7 days of incubation (Figure 2B1). In
an in Vitro model (i.e., cell medium containing sodium
citrate),
48,49 fcc-FePt-A NPs were found to release as little Fe
as Feridex (Figure 2B2), with ∼5% Fe found to be released
after 24 h and 20% after 7 days. This conﬁrms that the low pH
in the endosome/lysosome environment is not sufﬁcient to
dissolve the NPs and that the presence of endogenous citrate
or similar metallic chelates is instrumental to the NPs degrada-
tion by binding to solubilized Fe atoms.
48,49 The results
presented herein are signiﬁcant as they suggest that, when
considering the Fe release, the safety of fcc-FePt-A NPs is
comparable to that of Feridex under similar experimental
conditions. The chemical stability of the fcc-FePt-A NPs is also
supported by the Prussian blue staining experiments (Figure
2C1-C3).
(52) Xu, C.; Yuan, Z.; Kohler, N.; Kim, J.; Chung, M. A.; Sun, S. J. Am.
Chem. Soc. 2009, 131, 15346–15351.
(53) Crichton, R. R.; Wilmet, S.; Legssyer, R.; Ward, R. J. J. Inorg.
Biochem. 2002, 91, 9–18.




b coating cells [NPs] (µg/mL) [Fe] (µg/mL) tinc (h) cell damage (%) ref
FePt-CoS2 Fe(CO)5 CoS2 shell HeLa 1.5 ∼0.007 24 50 39
FePt-Cys Fe(CO)5 cysteine HeLa 5 ∼0.7 24 ∼10 39
15.5 ∼2.5 24 50
FePt-Fe2O3 Fe(CO)5 Fe2O3 shell, L-DOPA coating HeLa ∼8.3 ∼0.045
c 24 50 37
∼3.8
d
FePt-Fe3O4 Fe(CO)5 Fe3O4 shell HeLa 40 e 24 ∼10 37
10 e 72 ∼10
20 e 72 ∼30
FePt-COOH Fe(CO)5 bilayer of phospholipid
(DSPE-PEG(2000) carboxylic acid lipid)
and oleic acid/oleylamine
HeLa ∼10.7 1.72 24 ∼40 52
A431 ∼10.7 1.72 24 ∼40
SK-BR3 ∼10.7 1.72 24 ∼20
HEK-293 ∼10.7 1.72 24 ∼30
A2780 ∼7.8 1.25 24 50
FePt-SiO2-A Na2Fe(CO)4 SiO2 shell A375M, MCF7, U2OS 200 ∼2 168 0 f
FePt-A Na2Fe(CO)4 cysteamine A375M, MCF7, U2OS 30 ∼5.3 168 0 f
60 ∼10.5 72 ∼10
a Listed are NPs’ structure, precursors, and coating; “cells” stands for the cell line; [NPs] is the nanoparticle concentration; tinc is the incubation time;
cell damage is that after incubation.
b Pt precursor always Pt(acac)2.
c Fe contribution from Fe2O3 shell not included.
d Fe contribution from Fe2O3 shell
included.
e [Fe] cannot be calculated.
f Data presented in this work.
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certainly contributes to the NPs’ noteworthy low cytotoxicity.
Of course, iron release is only one parameter that contributes
to toxicity. It is quite possible that differences in the NPs
preparation, surface coating, ligand exchange, and extraction
protocols could account for the spread of the cytotoxicity data
reported in the literature. The toxicity may not necessarily be
due to the material itself through the release of its constituent.
In the present study, we used Collman’s reagent, Na2Fe(CO)4,
to control the FePt NPs stoichiometry and to ensure the
simultaneous presence of Fe and Pt species during the formation
of FePt alloy NPs; the use of Fe(CO)5 has been shown to form
NPs with a core and a shell rich in platinum and iron,
respectively.
31 After ligand exchange, the extraction process was
repeated up to six times to ensure removal of hazardous
chemicals such as chloroform, oleic acid, and oleylamine, while
the thiol group provides a strong bond between the cysteamine
and the NPs’ surface, preventing the ligands from becoming
lethal. During the review of this publication, cysteamine-coated
FePt NPs were reported to induce, after 24 h, very low cell
damage on Veron cells;
38 however, it is noticeable that the
strong bonding to the surface of the NPs, protecting them from
the cells’ environment, can be contrasted with, for instance, a
coating made with a bilayer structure of phospholipids and oleic
acid/oleylamine.
52 Indeed, even though this phospholipid ap-
proach provides aqueous solubility, it is also characterized by
a weaker bonding strength and a more dynamic behavior,
allowing the coating to slowly disperse in the cell. By doing
so, the “free” ligands can alter the cell viability as well as the
release of the NP constituents as the surface of the particles is
exposed to the cell, and the NPs’ chemical integrity can be
compromised further. Such outcomes have been reported by
Xu et al., although they elegantly focused on the opportunity
this provided to use the NPs as metal reservoirs to kill cancer
cells.
52
While the very high chemical stability of fcc-FePt-A NPs
was demonstrated in this report, cytotoxicity is observed at high
concentrations above 30 µg/mL FePt and long incubation times.
This could be explained by contributions from (i) the very small
release of Fe, which has been found to be <1% after 168 h and
(ii) the high concentration of positive surface charges, which
could also interact with the more negatively charged cell
membranes and induce membrane disruption.
54 In addition,
ligands with strong anchoring groups can reduce the toxicity,
as illustrated in this publication, and it is noticeable that the
present results were obtained with commercially available
ligands (i.e. cysteamine), so one should expect enhanced
viability from, for instance, custom-made dithiolate ligands, such
as those developed recently for quantum dots.
55,56 These could
provide cell viability at NP concentrations higher than 30 µg/
mL.
In this context, the little consistency observed when consider-
ing FePt NPs’ cytotoxicity data available in the literature stresses
that the measured toxicity should always be associated with the
nanocolloids, i.e. inorganic NPs + organic stabilizer. The
interplay between the components will indeed contribute to
the cytotoxicity results, with, for instance, a weak bonding to
the NPs’ surface increasing the probability of the nanocolloids
being toxic. It then appears that, to be able to compare
cytotoxicity data in a meaningful way, one must to develop and
use standardized approaches including the correlation between
(i) the evolution of the nanocolloids’ integrity, relying on both
the inorganic NPs and the organic stabilizers, and (ii) the cell
viability. It should be noticed that, in the context of apparently
toxic NPs, the nanocolloids’ solution stability could easily be
measured by, for instance, time-resolved transmission monitored
sedimentation experiments, as while the ligands come off the
NPs’ surface, the NPs tend to aggregate and fall out of solution.
The cellular internalization of Feridex is poor due to the weak
binding of the neutral dextran coating to the plasma membrane,
which limits the capability of cell internalization by the ﬂuid-
phase endocytosis pathway.
57,58 Enhancing cellular uptake of
dextran-coated NPs is possible with transfection agents and
further surface functionalization but was not relevant to the
present study.
44 In contrast, the amine-coated FePt NPs, fcc-
FePt-A and fcc-FePt-Silica-A, are efﬁciently internalized directly
without requiring the use of any external mediation such as
transfection agents or electroporation, illustrated with non-
phagocytic human cells in Figure 2D1. The uptake appears to
be mediated via macropinocytosis, a nonspeciﬁc endocytic
process, which involves the internalization of large areas of
plasma membrane together with signiﬁcant amounts of ﬂuid
(Figure 2D2). Irregular macropinosome vesicles larger than 1
µm are usually generated when membrane protrusions fuse back
to the plasma membrane (SI-Figure 6A).
43,50,51 Other pathways
could be involved, e.g., lipid raft-dependent mechanisms or the
clathrin-dependent pathway;
50,51,59,60 however, we did not
observe any evidence supporting their involvement. Further
studies are needed to clarify the exact cellular internalization
mechanism. However, and as expected once inside the cells,
the FePt NPs that are stabilized by Coulombic interactions
appear to be conﬁned in speciﬁc subcellular organelles, most
likely endosomes and lysosomes (Figure 2D3). This is of
signiﬁcant importance when developing FePt NPs-based bio-
medical platforms and can be attributed to the interplay between
the cationic surface of the NPs and the negatively charged cell
membrane.
By considering a family of FePt NPs, we established that,
despite the attractiveness of the silica coating, it weakens the
NPs’ magnetic moment and their applicability in clinical MRI.
This may be the result of a reduction of the magnetic effective
volume and/or an alteration of the material. In support of this
interpretation, the strong base environment associated with the
silica coating can partially oxidize the FePt surface, resulting
in a thin layer of softer magnetic material like iron oxide or
iron silicide, which because of its thinness is not visible by XRD
or TEM.
61,62
The fcc-FePt-A NPs demonstrated a very high MRI relaxivity
r2, which can be attributed to the combination of (i) an
intrinsically high magnetic moment, (ii) a thin organic coating,
(54) Bilensoy, E. Exp. Opin. Drug DeliV. 2010, 7, 795–809.
(55) Han, G.; Mokari, T.; Ajo-Franklin, C.; Cohen, B. E. J. Am. Chem.
Soc. 2008, 130, 15811–15813.
(56) Mei, B. C.; Susumu, K.; Medintz, I. L.; Mattoussi, H. Nat. Protoc.
2009, 4, 412–423.
(57) Arbab, A. S.; Bashaw, L. A.; Miller, B. R.; Jordan, E. K.; Lewis,
B. K.; Kalish, H.; Frank, J. A. Radiology 2003, 229, 838–846.
(58) Arbab, A. S.; Yocum, G. T.; Wilson, L. B.; Parwana, A.; Jordan, E. K.;
Kalish, H.; Frank, J. A. Mol. Imaging 2004, 3, 24–32.
(59) Dausend, J.; Musyanovych, A.; Dass, M.; Walther, P.; Schrezenmeier,
H.; Landfester, K.; Mailander, V. Macromol. Biosci. 2008, 8, 1135–
1143.
(60) Raffa, V.; Ciofani, G.; Vittorio, O.; Riggio, C.; Cuschieri, A.
Nanomedicine 2010, 5, 89–97.
(61) Lee, D. C.; Mikulec, F. V.; Pelaez, J. M.; Koo, B.; Korgel, B. A. J.
Phys. Chem. B 2006, 110, 11160–11166.
(62) Thomson, T.; Terris, B. D.; Toney, M. F.; Raoux, S.; Baglin, J. E. E.;
Lee, S. L.; Sun, S. J. Appl. Phys. 2004, 95, 6738–6740.
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a sample. While this combination created very effective T2 MRI
contrast agents even at µg/mL concentrations, these results also
underline the importance of engineering the interface of NPs
and demonstrate that a strong magnetic moment such as that of
FePt, combined with a thin coating layer having an open
molecular structure allowing very close aqueous proximity, are
essential parameters for the design of new generations of
diagnostic and therapeutic MRI contrast agents.
Finally, we demonstrate that FePt NPs can be successfully
used as a potent cellular and in ViVo MRI probes. This is
illustrated by both cell MRI (Figure 3B) and distinct hypointen-
sity of ∼1 mm in size observed in the in ViVo environment into
which the FePt NPs were injected (Figure 3D and SI-Figure 8).
43
Their more than 6 times higher relaxivity r2 allows using less
NPs than with iron oxide contrast agents such as Feridex, which
makes FePt NPs very promising contrast agents to identify small
lesions such as lymph node metastases.
4. Conclusion
In conclusion, we have presented the synthesis and charac-
terization of a family of FePt NPs: fcc-FePt-A NPs and fcc-
FePt-silica-A NPs. The reduction of magnetic properties ob-
served with both SQUID magnetometry and MRI relaxivity of
silica-coated NPs is attributed to the formation of very thin layers
of oxides and silicides. In sharp contrast with some previous
reports, our biocompatibility studies clearly demonstrate and
explain the absence of cytotoxicity at concentrations below 30
µg/mL, even after 7 days of incubation. The biocompatibility
is mainly attributed to the strong surface coating and the
extraction protocols. Another striking feature for cellular imag-
ing is the ability of the FePt NPs to efﬁciently enter tumor cells
without requiring any external mediation. The cellular uptake
by non-phagocytic tumor cells occurs via an apparent macro-
pinocytosis mechanism. The 7.1 T MRI studies, in Vitro and in
ViVo, have conﬁrmed that both fcc-FePt-A and fcc-FePt-silica-A
NPs are stronger T2 contrast agents than commercial Feridex,
with fcc-FePt-A T2 relaxivity (r2) being more than 6 times larger.
The superior capability of MRI contrast enhancement associated
with the FePt NPs makes them an ideal platform for the design
of diagnostic and therapeutic agents for image-guided magnetic
drug delivery and hyperthermic tumor ablation. The ﬁndings
of this study underline the importance of engineering magnetic
NP interfaces combining intrinsically strong magnetic moment
with coating layers. Finally, our studies have also demonstrated
that FePt NPs can be used successfully for cellular and in ViVo
imaging, thus conﬁrming the potential of FePt NPs in regenera-
tive medicine and stem cell therapy.
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